DavidEAviganMD

Hematologic Oncology

Associate Professor, Medicine, Harvard Medical School; Professor of Medicine, Medicine, Harvard Medical School; Active Staff, Hematology-Oncology, Beth Israel Deaconess Medical Center

Join to view full profile

Are you Dr. Avigan?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 115 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
330 Brookline Ave
Beth Israel Hospital
Boston, MA 02215
Phone+1 617-667-9920
Is this information wrong?

Summary

Dr. David Avigan, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is an Associate Professor at Harvard Medical School; Professor of Medicine.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1989 - 1993
Yale School of MedicineClass of 1989

Certifications & Licensure

MA State Medical License 1996 - 2025

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation Start of enrollment: 1998 Jun 01
Unknown status
Phase 1
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Jul 01
Withdrawn
Phase 1, Phase 2
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Phase I Study of Sequential Cord Blood Transplants Start of enrollment: 2003 May 01
Completed
Phase 1
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Start of enrollment: 2004 Oct 01
Completed
Phase 1, Phase 2
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma Start of enrollment: 2005 Apr 01
Completed
Phase 1
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma Start of enrollment: 2004 Jul 01
Completed
Phase 1
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Start of enrollment: 2002 Dec 01
Completed
Phase 2
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 Start of enrollment: 2009 Dec 01
Terminated
Phase 1, Phase 2
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma Start of enrollment: 2002 Dec 01
Completed
Phase 1, Phase 2
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Start of enrollment: 1999 Jul 01
Completed
Phase 2
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant Start of enrollment: 2008 Jun 01
Completed
Phase 1
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod Start of enrollment: 2008 Aug 01
Active, not recruiting
Phase 2
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2008 Sep 01
Completed
Not Applicable
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation Start of enrollment: 2010 Mar 01
Active, not recruiting
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
Terminated
Phase 1
Reduced Intensity Double Umbilical Cord Blood Transplantation Start of enrollment: 2011 Dec 01
Completed
Phase 2
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Start of enrollment: 2012 Nov 01
Completed
Phase 1
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
Completed
Phase 1
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Mar 03
Terminated
Phase 1
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Active, not recruiting
Phase 1, Phase 2
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Start of enrollment: 2020 Jun 30
Active, not recruiting
Phase 1, Phase 2
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2021 May 13
Active, not recruiting
Phase 1
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Anita G Koshy, Haesook T Kim, Jessica Liegel, Jon Arnason, Vincent T Ho, Joseph H Antin, Robin Joyce, Corey Cutler, Mahasweta Gooptu, Sarah Nikiforow, Emma K Logan, Pa...> ;Blood. 2023 Jun 15
2 citations
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.
Brian M Russell, David E Avigan> ;International Journal of Hematology. 2023 May 1
6 citations
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.
William Pilcher, Beena E Thomas, Swati S Bhasin, Reyka G Jayasinghe, Lijun Yao, Edgar Gonzalez-Kozlova, Surendra Dasari, Seunghee Kim-Schulze, Adeeb Rahman, Jonathan P...> ;NPJ Genomic Medicine. 2023 Jan 26
117 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...
Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim, Fabio M Iwamoto, David D Tran, George Ansstas, Charles S Cobbs, Jason A Heth, Michael E S...> ;JAMA Oncology. 2023 Jan 1
4 citations
Personalized tumor vaccine for pancreatic cancer.
Shira Orr, Ling Huang, James Moser, Dina Stroopinsky, Omar Gandarilla, Cori DeCicco, Jessica Liegel, Cansu Tacettin, Adam Ephraim, Giulia Cheloni, Daniela Torres, Dona...> ;Cancer Immunology, Immunotherapy. 2023 Feb 1
139 citations
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
10 citations
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial.
Vincent T. Ho, Haesook T. Kim, Jennifer Brock, Ilene Galinsky, Heather Daley, Carol Reynolds, Augustine Weber, Olga Pozdnyakova, Mariano Severgnini, Sarah Nikiforow, C...> ;Blood Advances. 2021 Nov 22
1 citations
Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma
Jared T. Ahrendsen, Kartik Sehgal, Sasmit Sarangi, Erik J. Uhlmann, Hemant Varma, Jon E. Arnason, David Avigan> ;Journal of Hematology. 2021 Oct 5
3 citations
Case Report: Refractory Cryptosporidiosis after CAR T-Cell Therapy for Lymphoma.
Caitlin A Trottier, Christina F Yen, Grace Malvar, Jon E. Arnason, David Avigan, Carolyn D. Alonso> ;The American Journal of Tropical Medicine and Hygiene. 2021 Jul 8
528 citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin,...> ;Lancet. 2021 Jul 24
15 citations
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model
Dina Stroopinsky, Jessica Liegel, Manoj Bhasin, Giulia Cheloni, Beena E Thomas, Swati S. Bhasin, Ruchit Panchal, Haider Ghiasuddin, Maryam Rahimian, Myrna Nahas, Shira...> ;Haematologica. 2021 Feb 4
5 citations
Vaccination as Immunotherapy in Hematologic Malignancies.
Jessica Liegel, Matthew Weinstock, Jacalyn Rosenblatt, David Avigan> ;Journal of Clinical Oncology. 2021 Jan 12
62 citations
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo.
Eleni Anastasiadou, Anita G. Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Lauren C. Pinter-Brown, Linda A Pestano, Cinzia Marchese, D...> ;Clinical Cancer Research. 2021 Feb 15
2 citations
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402...
Francine M. Foss, Xin Victoria Wang, Selina M. Luger, Opeyemi Jegede, Kenneth B. Miller, Edward A. Stadtmauer, Theresa L. Whiteside, David Avigan, Randall D. Gascoyne,...> ;Transfusion. 2020 Jul 12
24 citations
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
, , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2020 Jul 1
4 citations
Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A. Holstein, Alan Howard, David Avigan, Manisha Bhutani, Adam D. Cohen, Luciano J. Costa, Madhav V. Dhodapkar, Nicole J. Gormley, Damian J. Green, Jens Hillengas...> ;Biology of Blood and Marrow Transplantation. 2020 Jun 24
48 citations
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Matthew S. Davids, Haesook T. Kim, Caitlin Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo O. Maegawa, Alexandra Savell, Michael Mazzeo, Adrienne Anderson, Alex...> ;Blood. 2020 Jun 11
2 citations
Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation
Zachariah DeFilipp, Robert S. Makar, Jami Brown, David Avigan, Yi Bin Chen, Corey Cutler, Karen K. Ballen, David J. Kuter> ;Bone Marrow Transplantation. 2020 Jun 1
3 citations
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.
Zachariah DeFilipp, Shuli Li, David Avigan, Philippe Armand, Vincent T. Ho, John Koreth, Sarah Nikiforow, Edwin P. Alyea, Jerome Ritz, Vassiliki A. Boussiotis, Jacalyn...> ;Bone Marrow Transplantation. 2020 Apr 1
21 citations
Alisertib Plus Induction Chemotherapy in Previously Untreated Patients With High-Risk, Acute Myeloid Leukaemia: A Single-Arm, Phase 2 Trial
Andrew M. Brunner, Traci M. Blonquist, Daniel J. DeAngelo, Malgorzata McMasters, Geoffrey Fell, Nicole M. Hermance, Eric S. Winer, R. Coleman Lindsley, Gabriela S. Hob...> ;The Lancet. Haematology. 2020 Feb 1
6 citations
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Sarah A Holstein, Zaid Al-Kadhimi, Luciano J Costa, Theresa Hahn, Parameswaran Hari, Jens Hillengass, Nikhil C Munshi, Stefania Oliva, Marcelo C Pasquini, Qian Shi, Ed...> ;Biology of Blood and Marrow Transplantation. 2020 Jan 1
Advances in the development of vaccines and other immunotherapies for multiple myeloma.
David Avigan> ;Clinical Advances in Hematology & Oncology. 2019 Dec 1
52 citations
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study
Maria-Victoria Mateos, Robert Z. Orlowski, Enrique M. Ocio, Paula Rodriguez-Otero, Donna E. Reece, Philippe Moreau, Nikhil C. Munshi, David Avigan, David S. Siegel, Ra...> ;British Journal of Haematology. 2019 Sep 1
30 citations
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert A. Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ep...> ;Blood. 2019 Aug 15
49 citations
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.
Vincent Ribrag, David Avigan, Damian J. Green, Trisha Wise-Draper, Juan G Posada, Ravi Vij, Ying Zhu, Mohammed Z.H. Farooqui, Patricia Marinello, David S. Siegel> ;British Journal of Haematology. 2019 Aug 1
Join now to see all

Press Mentions

Researchers Discuss Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 11th, 2022
Researchers Discuss the Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 10th, 2022
Undeterred: BIDMC Cancer Center Symposium Goes VirtualDecember 4th, 2020
Join now to see all

Hospital Affiliations

Beth Israel Deaconess Medical CenterBoston, Massachusetts